Small molecule · Inhibitor of MET proto-oncogene, receptor tyrosine kinase (c-Met, HGF receptor) (MET) · developed by Novartis Pharm
Capmatinib is an orally bioavailable kinase inhibitor that selectively binds the MET receptor tyrosine kinase, including the exon 14-skipping variant, and blocks its phosphorylation and downstream signaling. It is studied in non-small cell lung cancer driven by MET alterations.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Dec 15, 2025). Read the full label for the exact wording, limitations and safety information.
EGFR-mutant Non-small Cell Lung Cancer
Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →